The New Product That Skipped the Gate
A dealer member launches a structured note linked to a volatility index, marketed to retail clients with a minimum investment of $10,000. The product was designed by the dealer's structured products desk. The new product committee reviewed a one-page summary and approved it in a 20-minute meeting; no one from compliance or the suitability function attended. The note has a 7-year term, a 40% downside buffer, and a 2.25% annual embedded fee. Six weeks after launch, $46M has been sold to 1,100 clients, 38% of whom are over 65 and 22% of whom have stated objectives of 'income' or 'capital preservation.' The sales force was trained in a 30-minute webinar that described the note as 'principal protected.' The CCO learns of the 'principal protected' description from a client email.
1. What are the product governance failures, and what immediate action is required?
Read the worked answer
The product governance failures are serious and multiple. (1) The new product committee approved a complex, illiquid, 7-year note on a one-page summary with no compliance or suitability representation - that is not a review, it is a formality. (2) No target market was defined with sufficient specificity; the actual sales distribution (38% over 65, 22% with income or capital preservation objectives) shows the product reached clients for whom it was plainly unsuitable. (3) The training described the note as 'principal protected' when the structure has only a 40% downside buffer and a 7-year term with embedded fees - that is a material misdescription. (4) The embedded fee and term were not adequately disclosed in the sales process. (5) There was no post-launch monitoring to catch the distribution drift.
Immediate action: suspend further sales of the note pending review; preserve all marketing, training, and sales records; identify every client who purchased and segment by suitability; stop using the 'principal protected' description and issue a correction to the sales force in writing; and notify the new product committee chair and senior management. The CCO should also assess whether the misdescription requires a regulatory notification and whether clients who were misled are entitled to remediation.
2. How should the CCO design the remediation and the go-forward product approval process?
Read the worked answer
Remediation should be risk-based. Segment the 1,100 clients by age, stated objective, concentration (the $10,000 minimum against a client's assets), and whether the 'principal protected' language appears in their records. Prioritize clients over 65 with income or preservation objectives and high concentration. For each, review the suitability file; where the sale cannot be justified, offer to unwind at no cost to the client or provide make-whole compensation. Document the standard applied and the rationale for each decision, and report the outcome to the regulator if required.
Go-forward process: (1) Require compliance and suitability sign-off as voting members of the new product committee, with a documented product risk assessment. (2) Mandate a written target market definition and a negative target market, and build a pre-trade eligibility check so the product cannot be sold outside it without exception approval. (3) Require plain-language disclosure of term, buffer, fees, and liquidity, reviewed by compliance before use. (4) Prohibit unapproved marketing language and require training materials to be compliance-approved and tested. (5) Institute post-launch monitoring at 30, 90, and 180 days against the target market, with a trigger to suspend sales if distribution drifts. (6) Keep minutes that record the substance of the review, not just the approval.
3. The desk head argues the note was 'appropriate for sophisticated retail investors' and that the CCO is second-guessing a commercial decision. How should the CCO respond?
Read the worked answer
The CCO should separate the commercial question from the conduct question. Whether the note is a good product is a commercial judgment; whether it was sold to the right clients, described accurately, and approved through a real control is a compliance judgment, and that is squarely the CCO's remit. The distribution data - 38% over 65, 22% with income or preservation objectives - is not a matter of opinion; it is evidence that the target market was not respected.
The 'sophisticated investor' argument also fails on its own terms: a 30-minute webinar that called the note 'principal protected' is not sophisticated disclosure, and a client with a capital preservation objective is not a sophisticated buyer of a 7-year volatility-linked note regardless of wealth. The CCO should say plainly that the 'principal protected' description is a misstatement that creates legal and regulatory exposure, and that correcting it is not optional.
Finally, the CCO should route the disagreement to the board or a senior conduct committee with a written record of both positions. A CCO who is overruled should ensure the override is documented and escalated, not absorbed quietly.